Tuttle Capital Management’s Biogen BIIB Stock Holding History

Tuttle Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-593	Closed	-$172K	–	138
2018 Q2	$172K	Buy	+593	New	+$167K	0.12%	102

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Tuttle Capital Management's BIIB Position: Q3 2018 in Review

Tuttle Capital Management sold out of Biogen (BIIB) in Q3 2018, closing a stake of 593 shares — an estimated $172K sold.

Tuttle Capital Management first reported a position in BIIB in Q2 2018 and held it in 1 quarter. The position peaked at $172K in Q2 2018. 1,145 funds tracked by Wall St. Rank hold BIIB as of Q3 2018.

Tuttle Capital Management reported no remaining Biogen position as of Q3 2018 after selling out during the quarter.
Tuttle Capital Management sold 593 Biogen shares in Q3 2018, an estimated $172K.
Tuttle Capital Management first reported a position in Biogen in Q2 2018 and held it in 1 quarter.
Tuttle Capital Management's Biogen position peaked at $172K in Q2 2018.
1,145 funds tracked by Wall St. Rank held Biogen as of Q3 2018.

Based on Tuttle Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.